Drug
Ivacaftor
Ivacaftor: highest development phase Phase 3, developed by Vertex Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Vertex Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ivacaftor NCT02742519 | Phase 3 | Cystic Fibrosis |
| Ivacaftor NCT04066751 | Phase 2 | Chronic Obstructive Pulmonary Disease |
Latest
No recent events.
Follow Ivacaftor on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.